Safety and Efficacy Trial of the Use of Quetiapine Fumarate (SEROQUEL®) in the Treatment of Patients with Bipolar Depression
Study identifier:5077US/0049
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
-
Medical condition
Bipolar Disorder
Phase
Phase 3
Healthy volunteers
No
Study drug
SEROQUEL (quetiapine fumarate) Tablets
Sex
All
Actual Enrollment
-
Study type
Interventional
Age
18 Years - 65 Years
Date
Study Start Date: 01 Sept 2002
Primary Completion Date: 01 Sept 2003
Study Completion Date: 01 Sept 2003
Study design
Allocation: None
Endpoint Classification: None
Intervention Model: None
Masking: None
Primary Purpose: Treatment
Verification:
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
